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INTRODUCTION
Renal cancer is among the 10 most common cancers in 
both males and females. For reasons that are not totally 
clear, the rate of new kidney cancers has been rising since 
the 1990 s, although this seems to have leveled off in the 
last few years. Part of this rise is probably due to the use 
of newer imaging tests such as CT scans, which are able to 
identify some cancers which may have otherwise remained 
undetected.1
The accuracy of current imaging techniques in differen-
tiating between renal cell carcinoma (RCC) and some 
benign tumors such as oncocytoma, which account for 
3–5% of all renal neoplasms in adults 2–4 is low. In fact, 
differentiation between RCC and oncocytomas is usually 
based on the histologic findings of the surgically removed 
tumor. This difficulty in differentiating between RCC and 
oncocytomas using imaging techniques is due to the 
increased vascularity of these lesions, showing enhance-
ment and washout, with reduced enhancement in the 
nephrographic phase leading to RCCs being mistakenly 
identified as oncocytomas in multidetector CT (MDCT) 
studies In a previous study, a multivariable predictive 
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Objective: The purpose of this study is to validate a 
multivariable predictive model previously developed to 
differentiate between renal cell carcinoma (RCC) and 
oncocytoma using CT parameters.
Methods and materials: We included 100 renal lesions 
with final diagnosis of RCC or oncocytoma studied 
before surgery with 4- phase multidetector CT (MDCT). 
We evaluated the characteristics of the tumors and the 
enhancement patterns at baseline, arterial, nephro-
graphic and excretory MDCT phases.
Results: Histopathologically 15 tumors were oncocy-
tomas and 85 RCCs. RCCs were significantly larger 
(median 4.4 cm vs 2.8 cm, p = 0.006). There were signif-
icant differences in nodule attenuation in the excre-
tory phase compared to baseline (median: 31 vs 42, p = 
0.015), with RCCs having lower values. Heterogeneous 
enhancement patterns were also more frequent in RCCs 
(85.9% vs 60%, p = 0.027).
Multivariable analysis showed that the independent 
predictors of malignancy were the enhancement 
pattern, with oncocytomas being more homogeneous 
in the nephrographic phase [Odds Ratio (OR) 0.16 (95% 
CI 0.03 to 0.75, p = 0.02)], nodule enhancement in 
the excretory phase compared to baseline, with RCCs 
showing lower enhancement [OR 0.96 (95% CI 0.93 to 
0.99, p = 0.005)], and a size > 4 cm, with RCCs being 
larger [OR 5.89 (95% CI 1.10 to 31.58), p = 0.038].
Conclusion: The multivariable predictive model previ-
ously developed which combines different MDCT 
parameters, including lesion size > 4 cm, lesion enhance-
ment in the excretory phase compared to baseline and 
enhancement heterogeneity, can be successfully applied 
to distinguish RCC from oncocytoma.
Advances in knowledge: This study confirms that 
multiparametric assessment using MDCT (including 
parameters such as size, homogeneity and enhancement 
differences between the excretory and the baseline 
phases) can help distinguish between RCCs and oncocy-
tomas. While it is true that this multiparametric predic-
tive model may not always correctly classify renal tumors 
such as RCC or oncocytoma, it can be used to determine 
which patients would benefit from pre- surgical biopsy 
to confirm that the tumor is in fact an oncocytoma, and 
thereby avoid unnecessary surgical treatments.
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5 by combining different imaging parameters instead of 
addressing each parameter separately as previously reported 
in the literature. However, this model required validation in 
further studies. The purpose of this study is to validate a multi-
variable predictive model previously developed to differentiate 
between RCC and oncocytoma using CT parameters.
METHODS AND MATERIALS
Patients
In this retrospective study, we used our institutional database 
to identify consecutive patients who had undergone surgical 
management of renal tumors from August 2010 to December 
2014. For the purposes of this study, no institutional review 
board approval was required.
Patients who had pre- operative CT evaluation as per renal 
mass protocol of our institution (Hospital Clinic de Barcelona) 
including four phases (unenhanced, corticomedullary, nephro-
graphic and excretory) and had confirmed pathological diagnosis 
of either oncocytoma or RCC were included in this retrospective 
study.
A total of 99 patients and 100 lesions were included. One patient 
had two lesions (two oncocytomas). Seven patients were excluded 
because the scans were performed with a different protocol.
CT examination
The majority of MDCT studies were performed using a 64- row 
helical scanner (37 patients), a 2- row helical scanner (19 patients) 
(Somatom Sensation 64 and Emotion Duo, respectively, both 
from Siemens Medical Solutions, Erlangen, Germany) and a 
Dual Source 128- row scanner (31 patients) (Somatom Definition 
Flash, Siemens Medical Solutions, Erlangen, Germany). The scan 
parameters of the MDCT studies performed in our department 
are shown in Table 1 . 13 of the 99 CT scans were not performed 
in our institution, although those 13 patients had the same 
scan protocol of our center for renal mass characterization//but 
following a similar protocol (same phases, slice thickness and 
other technical parameters). All images were obtained in a single 
breath- hold using automatic tube current modulation (Care 
Dose 4D, Siemens Healthcare). Slices with a thickness of 5 mm 
and 2 mm were reconstructed in the axial plane in all phases. 20 
min before the study, all patients drank 500 ml of diluted oral 
contrast (Gastrografin, Bayer, 2%). All the studies involved the 
following phases: unenhanced, corticomedullary, nephrographic 
and excretory. Patients underwent unenhanced scanning of the 
abdomen down to the iliac crest. Patients also received 100 ml of 
non- ionic iohexol (Iopromide 300 mg I/mL; Bayer) injected with 
a power injector at a rate of 3 ml s−1 using a bolus tracking algo-
rithm (CareBolus, Siemens Medical Solutions; SmartPrep, GE 
Medical Systems) to calculate the bolus arrival time at the aorta. 
For bolus tracking, a threshold was set at 100 HU with a region 
of interest (ROI) located at the ascending aorta in the thora-
coabdominal CT scans, and in the descending in the abdominal 
CT scans. Corticomedullary phase imaging was done 6 s after 
the threshold was reached. Nephrographic phase imaging was 
performed after 90 s after the start of injection. Excretory phase 
imaging was done after 3 min after the start of injection.
CT image analysis
Images were transferred to our picture archiving and communi-
cation system (RAIMSERVER) and were reviewed and analyzed 
using RAIM ALMA 3D software (2019; v. 4.2.2.6).
Two radiologists with 3 (AS, resident) and 9 (BP, genitourinary 
radiologist) years of experience in body radiology independently 
interpreted the CT studies and consensus was obtained in case of 
discrepancy. Both readers were aware of the presence of a renal 
tumor but were blinded to clinical and pathologic information.
The readers were asked to evaluate all the parameters included 
in the multivariable predictive model, on axial CT scan images 
(5 mm slices).
• Qualitative parameters
 – Type of enhancement: homogeneous or heterogeneous 
(assessed in the nephrographic phase). Tumors with non- 
enhancing areas or with low attenuation areas were described 
as heterogeneous and tumors with uniform enhancement were 
described as homogeneous.
• Quantitative parameters
 – Size: maximum diameter of the lesion in axial images.
 – Attenuation value: the difference between the mean 
attenuation value for each nodule and the mean attenuation 
Table 1.  Scan parameters
Parameters 128- row scanner 64- row scanner 2- row scanner
Detector colimation 128 × 1.2 mm 64 × 0.6 mm 2 × 4 mm
Effective section thickness 1.2 mm 0.6 mm 2 mm
Reconstruction increment 5 mm 5 mm 5 mm
Gantry rotation time 0.5 s 0.5 s 0.8 s
Pitch 0.6 1.35 1.6
Effective current 240 mAs 120 mAs 130 mAs
Tube voltage 120kVp 120 kVp 110 kVp
Kernel reconstruction B20 B20 B40s
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value in the baseline images was calculated for the excretory 
phase. For the analysis of the magnitude of enhancement, 
ROIs with a size between 0.5 and 1 cm2 were placed on the 
most avid areas of enhancement of heterogeneous lesions, 
avoiding the focal hypoattenuating areas, and in the central 
area of homogeneous lesions (Figures 1 and 2). Enhancement 
differences during the excretory phase in relation to the 
unenhanced phase for absolute enhancement of the nodule 
were abbreviated as N3- N0.
Prior multivariable model
For each lesion, we calculated the model equation constructed in 
the previous study. For values of X, the c regression coefficients 
are multiplied by 0 (no) or 1 (yes) for binary variables and by the 
actual continuous values otherwise:
SCORE= 5.3852 + (−1.7122 × X1 ) + (1.3891 × X2 ) + (−0.0758 
× X3 )
5.3852 = slope; −1.7122 = B1; 1.3891 = B2; −0.0758 = B3
X1 : Homogeneous enhancement (one if YES and 0 if NO).
X2 : Size larger than 4 cm (one if YES and 0 if NO).
X3 : Difference in attenuation for the excretory phase compared 
to the unenhanced phase (absolute value).





As per mathematical nomenclature, e represents the exponent. 
The model provides the probability of a patient having RCC on a 0 
to 1 scale, where 1 means having RCC and 0 means having onco-
cytoma. Therefore, for values closer to 1, the higher the probability 
of having RCC. An example of application is shown in Figure 3 .
Statistical analysis
Patient and imaging characteristics were described overall and 
by pathologic type. One patient had two lesions and no adjust-
ments were made for intra patient correlation.
All the descriptive data are expressed as median (range) and 
frequencies (%) unless specified otherwise. We validated the 
previously published model with receiver operative curve (ROC) 
analysis. We used the Wilcoxon Rank Sum test, Fisher’s Exact 
test, and logistic regression to assess the association between 
continuous and categorical imaging parameters with a patho-
logic diagnosis of RCC.
Two- sided p- values lower than 0.05 were considered statistically 




This study included 99 patients with 100 lesions. The median age 
of the patients studied was 66 years (range: 33 – 88 years), and 
68.7 % (68/99) were males. No significant differences in age or 
gender were found between RCC and oncocytoma lesions ( p 
> 0.95 for both) (Table 2). The mean time passed between the 
MDCT scan and the nephrectomy was 96 days (with minimum 
of 1 day and maximum of 331 days).
Lesion characteristics
Of the 100 renal lesions included in this study, 15 were onco-
cytomas (15%) and 85 were RCCs (85%). In the RCC group, 43 
Figure 1. ROC curve for the prior multivariate model. AUC, are 
uder the curve; ROC, receiver operating characteristic.
Figure 2. Multiphasic MDCT study (A) unenchanced phase, 
(B) corticomedullary phase, (C) nephrographic phase and (D): 
excretory phase) of 79- year- old male shows a 5.3 cm solid 
lesion with heterogeneus contrast enhancement in the middle 
third of the left kidney. ROIs were placed on the lesion and on 
the renal cortex in each phase, calculating the mean attenua-
tion ±SD. This lesion corresponded to a clear cell subtype of 
RCC. MDCT, multidetector CT; RCC,renal cell carcinoma; ROI, 
region of interest; SD, standard deviation.
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Table 2.  Characteristics of patients and renal lesions
All Patients RCC Oncocytoma p- value
Lesions  100 85 15
Patient characteristics
Age (years) Median (range) 65.5 (33 – 88) 66.0 (33 – 88) 68.0 (42 – 77) > 0.95
Gender Male 69 (69.0) 59 (69.4) 10 (66.7) > 0.95
Female 31 (31.0) 26 (30.6) 5 (33.3)
Lesion characteristics
Size (cm) Median (range) 3.9 (1.2 – 19.0) 4.4 (1.3 – 19.0) 2.8 (1.2 – 9.1) 0.006
Calcifications No 86 (86) 71 (83.5) 15 (100) 0.12
Yes 14 (14) 14 (16.5) 0 (0)
Cystic No 84 (84) 71 (83.5) 13 (86.7) > 0.95
Yes 16 (16) 14 (16.5) 2 (13.3)
Well defined No 29 (29) 26 (30.6) 3 (20) 0.54
Yes 71 (71) 59 (69.4) 12 (80)
Enhancement Heterogeneous 82 (82) 73 (85.9) 9 (60) 0.027
Homogeneous 18 (18) 12 (14.1) 6 (40)
RCC : renal cell carcinoma
Number represents frequency with percent of column in parentheses unless otherwise stated. Age and gender for all patients are out of 99 lesions, 
whereas all other measurements in the table are out of 100 lesions.
Figure 3. Multiphasic MDCT study (A) unenchanced phase, (B) corticomedullary phase, (C) nephrographic phase and (D): excre-
tory phase) of 44- year- old female shows a 3.7 cm solid lesion with homogeneus contrast enhancement in the middle third of the 
right kidney. ROIs were placed on the lesion and on the renal cortex in each phase, calculating the mean attenuation ± SD. This 
lesion corresponded to an Oncocytoma. MDCT, multidetector CT; ROI, region of interest; SD, standard deviation.
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were clear cell RCCs and 37 were low- grade RCCs, including 
papillary and chromophobe subtypes. In addition, there were 
three mixed RCC (one chromophobe +papillary, one clear cell 
+ chromophobe + papillary and one clear cell +papillary), one 
multilocular cystic RCC and one mucinous tubular RCC.
Tumor size
Tumor size was significantly larger in RCC lesions (median: 
4.4, range: 1.3. – 19.0) compared to oncocytomas (median: 2.8, 
range: 1.2 – 9.1, p = 0.006).
Pattern of enhancement
RCC lesions had a higher proportion of heterogeneous enhance-
ment (85.9%, 73/85) compared to oncocytomas (60%, 9/15) ( p 
= 0.027) (Table 2).
Magnitude of enhancement
Table 3 shows the continuous imaging parameter measurements 
overall and by pathologic type.
Difference between mean enhancement of the 
lesion and baseline attenuation (N-N0)
The difference in attenuation between the excretory and the 
unenhanced phase (N3- N0) was significantly lower in RCC 
lesions (median: 31.0, range: 9.0–112.0) compared to oncocy-
tomas (median: 42.0, range: 26.0–124.0) ( p = 0.015).
Figures 3 and 4 show examples of lesions in each group.
Multivariable predictive model validation in a new 
sample
The univariable and multivariable findings of the previous model 
are shown in Table 4. Similar to the previous findings published, 
the difference in the excretory phase compared to baseline 
remained significantly associated with the pathologic type, with 
a larger difference in the excretory phase compared to the unen-
hanced phase being associated with a lower probability of being 
RCC [oddsratio (OR): 0.96, 95% confidence interval (CI): 0.93 
– 0.99, p = 0.005). Similarly, homogeneous lesions had a signifi-
cantly lower odds ratio of being RCC lesions (OR: 0.16, 95% CI: 
0.03 – 0.75, p = 0.020) and lesions larger than 4 cm had a signifi-
cantly higher probability of being RCC (OR: 5.89, 95% CI: 1.10 
– 31.58, p = 0.038). The multivariable model developed in the 
previous study combining these parameters obtained an AUC of 
0.85 (95% CI: 0.77 – 0.92), indicating very good discrimination 
performance of the model in this new sample (Figure 1).
DISCUSSION
The results of this study confirm that the previously devel-
oped multivariable model, that combines size, enhancement 
pattern, and difference in attenuation for the excretory phase, 
can correctly classify solid renal lesions such as RCCs and 
oncocytomas in 85% of the cases, confirming and validating 
results obtained in the previous work assessed.5 In addition, 
given the higher risk shown by the univariable analysis (OR: 
7.31 [1.55 to 34.40] p = 0.012), a tumor size > 4 cm should 
always be taken into account as the first step in the absence of 
Table 3.  Imaging of RCC and oncocytomas
All Patients RCC Oncocytoma p- value
Attenuation (HU )
Unenhanced (N0) 30 (9 – 47) 30 (9 – 47) 28 (12 – 38) 0.34
Corticomedullary (N1) 85 (12 – 234) 85 (12 – 234) 87 (31 – 189) 0.59
Nephrographic (N2) 83 (26 – 229) 82 (26 – 229) 95 (41 – 150) 0.30
Excretory (N3) 65 (20 – 157) 63 (20 – 140) 72 (41 – 157) 0.08
Difference in attenuation (N- N0)
Corticomedullary (N1- N0) 52.5 (1.0 – 200.0) 53.0 (1.0 – 200.0) 51.0 (19.0 – 151.0) 0.40
Nephrographic (N2- N0) 56.0 (12.0 – 201.0) 53.0 (12.0 – 201.0) 63.0 (26.0 – 114.0) 0.16
Excretory (N3- N0) 34.5 (9.0 – 124.0) 31.0 (9.0 – 112.0) 42.0 (26.0 – 124.0) 0.015
Ratio of attenuation (N/C)
Unenhanced(R0) 1.07 (0.35 – 3.30) 1.10 (0.35 – 3.30) 1.00 (0.50 – 1.57) 0.13
Corticomedullary(R1) 0.75 (0.12 – 2.10) 0.76 (0.12 – 2.10) 0.70 (0.35 – 1.67) 0.73
Nephrographic(R2) 0.62 (0.20 – 1.14) 0.62 (0.20 – 1.14) 0.62 (0.35 – 0.99) 0.35
Excretory(R3) 0.61 (0.19 – 1.26) 0.61 (0.19 – 1.26) 0.69 (0.43 – 0.87) 0.07
Difference in attenuation ratios (N/C - N0/C0)
Corticomedullary(R1- R0) − 0.31 (-1.49 – 0.85) − 0.33 (-1.49 – 0.85) − 0.17 (-0.94 – 0.82) 0.29
Nephrographic(R2- R0) − 0.43 (-2.79 – 0.57) − 0.48 (-2.79 – 0.57) − 0.22 (-0.97 – 0.25) 0.035
Excretory(R3- R0) − 0.44 (-2.76 – 0.41) − 0.47 (-2.76 – 0.41) − 0.30 (-1.05 – 0.33) 0.021
RCC, renal cell carcinoma.
Numbers represent median with range in parentheses.
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other imaging data and deserves to be further explored. We 
consider that this multiparametric approach using MDCT has 
a higher accuracy for differentiating these types of tumors than 
previous approaches reported in the literature 4,6,7 in which 
these variables were analyzed independently. Despite the theo-
retical mathematical complexity of the formula, the applica-
tion in the daily routine practice is simple. In order to facilitate 
its application we attach a spreadsheet, in which it has to be 
filled with the four parameters explained previously (its appli-
cation can be performed in less than 1 min).
Different groups of patients could benefit from the applica-
tion of this model, particularly those with lesions smaller than 
4 cm, which is currently one of the most common scenarios 
in the clinical practice. Despite the fact that the American 
Urological Association has recently included the indication 
for biopsy of lesions in which the biopsy result can change 
the clinical management, 8,9 this indication is not generally 
included in European urological guidelines.10 In these guide-
lines, biopsy is not considered necessary in patients under-
going surgery for enhancing solid lesions. However, biopsy 
is recommended when a benign lesion is suspected. In these 
cases, the predictive model could help support the decision 
to perform the biopsy if the result of the predictive model 
is a suspicion of oncocytoma. In addition, the predictive 
model can be useful in the management of patients in whom 
a biopsy is recommended but cannot be performed due to 
technical difficulties (in small lesions located in superior 
and anterior or internal leaflets)11 or to comorbidities such 
as severe coagulation disorders. The suspicion of an oncocy-
toma can support a conservative management approach like 
active surveillance.
Despite the magnitude of enhancement remaining, the most 
studied independent variable for differentiation between RCCs 
and oncocytomas, there is still a lack of consensus about the 
optimal phase for this purpose. This is probably due to the 
heterogeneity that we observed in the MDCT protocol acquisi-
tions (involving the number of phases, time of acquisition since 
the arrival of the contrast, etc.). Some studies such as that by Coy 
et al reported significant differences in arterial phase enhance-
ment, considering this to be the optimal phase to help in this 
differentiation.12,13 However, our study suggests that the arterial 
phase is not helpful to differentiate RCC from oncocytoma, with 
the baseline and excretory phases being the most useful. Zhang 
et al.14 found no differences in excretory phase enhancement 
and also observed that both RCCs and oncocytomas are hyper-
vascular in the nephrographic phase (the arterial phase was not 
evaluated), concluding that no differentiation could be made 
between RCCs and oncocytomas. Similar to the previous study, 
in this new sample the excretory phase remained the optimal 
phase to distinguish these tumors, being especially relevant the 
difference of attenuation (N3- N0; p = 0.015) and the difference 
in attenuation ratios (R3–R0; p = 0.021) of the nodule in the 
excretory phase compared to the baseline phase. This fact, and 
especially the difference in attenuation ratios, allow the results 
to be standardized independently of the equipment used or the 
amount of contrast administered, and also independently of the 
characteristics of the patients (such as cardiac function), similar 
to what has been reported in other studies. 6,7 This relevant 
difference in contrast enhancement behavior between RCCs and 
oncocytomas could be explained by the latter characteristically 
showing a lower degree of washout in late phases. Lee- felker et al 
6 compared the degree of washout between the different phases in 
RCCs and oncocytomas and reported that the optimal parameter 
Figure 4. Example of multivariate model application with the cases shown previously on Figure 1 and 2.
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for their differentiation was the absolute de- enhancement value 
from the corticomedullary to the nephrographic phase. Perhaps 
the differences with our work might be explained by the acquisi-
tion time of the excretory phase, taking into account that in the 
Lee- Felker et al study the excretory phase was acquired at 8 min 
after contrast injection, whereas in our study it was acquired at 
3 min. Other studies have also evaluated the degree of washout 
between different phases but did not include the excretory 
phase.15
Another possible source of discordance among the 
different studies depends on manual placement of the 
region of interest (ROI). Subjectivity of ROI placement 
can generate inherent variations, both in the detection of 
the area of greatest uptake as well as in the size of the ROI. 
This problem could be solved by performing a voxel that 
includes the entire lesion.16 However, the use of this voxel 
manually requires additional analysis time. New software 
is being developed that segments the tumor automatically, 
simplifying the optimal placement of the ROI by automated 
algorithms (CAD), such as that described by Coy et al.12 
However, we obtained a higher AUC value compared to this 
method in the differentiation of RCC vs oncocytoma (0.85 vs 
, 0.79, respectively). In addition, other new resources of CT 
image analysis currently under investigation, such as texture 
analysis, could be the key to the development of a new multi-
parametric predictive model.17
Table 4.  Risk of malignancy estimated by univariable and multivariable logistic regression models considering significant varia-
bles from the standard univariable analysis and AUC- RO C
Univariable Multivariable
OR [95% CI] p- value OR [95% CI] p- value
Size > 4 cm > 4 cm 7.31 [1.55 - 34.40] 0.012 5.89 [1.10 - 31.58] 0.038
<= 4 cm REF REF
Enhancement Homogeneous 0.25 [0.07 - 0.82] 0.022 0.16 [0.03 - 0.75] 0.020
Heterogeneous REF REF
Size 1.47 [1.04 - 2.07] 0.028 ---
Unenhanced
(N0)
1.04 [0.97 - 1.11] 0.25 ---
Corticomedullary 
(N1)
1.00 [0.99 - 1.01] 0.55 ---
Nephrographic
(N2)
0.99 [0.98 - 1.01] 0.43 ---
Excretory
(N3)
0.98 [0.96 - 1.00] 0.06 ---
Corticomedullary 
(N1- N0)
1.00 [0.98 - 1.01] 0.42 ---
Nephrographic
(N2- N0)
0.99 [0.98 - 1.01] 0.29 ---
Excretory
(N3- N0)
0.97 [0.95 - 1.00] 0.021 0.96 [0.93 - 0.99] 0.005
Unenhanced
(R0)
4.52 [0.64 - 32.07] 0.13 ---
Corticomedullary
(R1)
1.26 [0.25 - 6.24] 0.78 ---
Nephrographic
(R2)
0.24 [0.01 - 4.89] 0.35 ---
Excretory
(R3)
0.06 [0.00 - 2.90] 0.15 ---
Corticomedullary
(R1- R0)
0.46 [0.11 - 1.88] 0.28 ---
Nephrographic
(R2- R0)
0.19 [0.03 - 1.13] 0.07 ---
Excretory
(R3- R0)
0.17 [0.03 - 1.01] 0.052 ---
AUC, area under the curve; 95% CI, 95% confidence interval; OR, odds ratio;ROC, receiver operating characteristic.
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Similar to the results of the previous study, in the present study 
other parameters besides the enhancement pattern were signif-
icant and have already been described in the literature as being 
more suggestive of RCC than oncocytoma. In our cohort, the 
most significant parameter for tumor discrimination was again 
the size, with the mean (SD) size of RCCs being larger than 
oncocytomas (4.4 cm vs 2.8 cm, respectively; p 0.006).
This finding agrees with reports by authors such as Thompson 
et al, who stated that the risk of malignancy and tumor grade 
are correlated to tumor size.18,19 Nevertheless, when tumor 
size is evaluated separately, this parameter alone cannot help 
distinguish malignant from benign tumors and is not a reliable 
predictor of malignancy.20 In fact, cases of small- sized tumors 
(<4 cm) with metastasis have been described in the literature.21
However, we consider that the association of size with other 
qualitative parameters, such as the enhancement pattern 
(homogeneous vs heterogeneous), is useful for the develop-
ment of a predictive model. A heterogeneous enhancement 
pattern has been associated with malignant renal lesions, 
particularly in the case of the RCC subtype.22 In our study, 
RCCs were also more heterogeneous lesions than oncocy-
tomas (85.9% vs 60%, respectively; p = 0.027). However, the 
tumor enhancement pattern is generally associated with its 
size, which is related to necrosis or hemorrhage being more 
commonly found in larger tumors.
The limitations of this study include its retrospective nature 
and the small number of oncocytomas included.19 However, 
our small sample should be viewed in the context of the low 
prevalence of these lesions. Other studies have reported similar 
or even smaller series of patients.4,13,14,23 Further, the lower 
bound of our AUC confidence interval (0.77) is still indicative 
of the good discrimination capacity of the model. We welcome 
the opportunity for future studies that involve additional 
treatment centers or have a wider time interval to increase 
the number of oncocytomas and allow for further validation 
of the predictive model. A theoretical limitation of this study 
is the utilization of different scanners. However, the positive 
result that we have obtained with this model could support its 
validation in the clinical daily practice. Another limitation is 
that analysis of different RCC subtypes was not made. We have 
not made the differentiation between the different histological 
subtypes of RCC because the objective of this work is allowing 
to suggest if a renal lesion is benign or malignant, regardless 
of the RCC subtype.
In conclusion, this study validates the usefulness of a MDCT 
predictive model (including parameters such as size, homoge-
neity and enhancement differences between the excretory and 
the baseline phases) in the differentiation between RCCs and 
oncocytomas. 
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